Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy

Breast Cancer Research and Treatment

Volumn 124, Issue 1, 2010, Pages 177-186

  Clemons, Mark ^h   Joy, Anil A ^a   Abdulnabi, Radhi ^b   Kotliar, Mauricio ^c   Lynch, Jodi ^d   Jordaan, Johan P ^e   Iscoe, Neill ^f   Gelmon, Karen ^g  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Clinical Data Services Division   (United States)

^c Sanatorio Guemes   (Argentina)

^d SUTHERLAND HOSPITAL   (Australia)

^e ADDINGTON HOSPITAL   (South Africa)

^f ELI LILLY AND COMPANY   (United States)

^g BRITISH COLUMBIA CANCER AGENCY   (Canada)

^h NONE

Author keywords

Anthracycline; Capecitabine; Enzastaurin; Metastatic breast cancer; Progression free survival; Taxane

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; ENZASTAURIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAXANE DERIVATIVE;

ADULT; ANOREXIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LEUKOCYTE; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUTROPHIL; NEUTROPHIL COUNT; OBESITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PORTAL VEIN THROMBOSIS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SODIUM BLOOD LEVEL; SUDDEN DEATH; THROMBOCYTOPENIA; THROMBOSIS; TUMOR LOCALIZATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARGENTINA; AUSTRALIA; BREAST NEOPLASMS; CANADA; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; FLUOROURACIL; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; MEXICO; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PLACEBO EFFECT; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SOUTH AFRICA; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77957708324     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1152-0     Document Type: Article

References (24)

1. A Moreno-Aspitia EA Perez 2009 Treatment options for breast cancer resistant to anthracycline and taxane Mayo Clin Proc 84 533 545 1:CAS:528:DC%2BD1MXnsVWqsrw%3D 10.4065/84.6.533 19483170
2. IC Henderson DA Berry GD Demetri CT Cirrincione LJ Goldstein S Martino JN Ingle MR Cooper DF Hayes KH Tkaczuk, et al. 2003 Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 976 983 1:CAS:528:DC%2BD2cXpsVGqs7c%3D 10.1200/JCO.2003.02.063 12637460
3. CM Walko C Lindley 2005 Capecitabine: a review Clin Ther 27 23 44 1:CAS:528:DC%2BD2MXis1WltLg%3D 10.1016/j.clinthera.2005.01.005 15763604
4. CM Barnett 2009 Survival data of patients with anthracycline- or taxane-pretreated or resistant metastatic breast cancer Pharmacotherapy 29 1482 1490 1:CAS:528:DC%2BD1MXhs1Sksb7N 10.1592/phco.29.12.1482 19947807
5. ES Thomas HL Gomez RK Li HC Chung LE Fein VF Chan J Jassem XB Pivot JV Klimovsky FH de Mendoza, et al. 2007 Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment J Clin Oncol 25 5210 5217 1:CAS:528:DC%2BD2sXhsVKnsbzO 10.1200/JCO.2007.12.6557 17968020
6. KD Miller LI Chap FA Holmes MA Cobleigh PK Marcom L Fehrenbacher M Dickler BA Overmoyer JD Reimann AP Sing, et al. 2005 Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer J Clin Oncol 23 792 799 1:CAS:528:DC%2BD2MXitVKitrk%3D 10.1200/JCO.2005.05.098 15681523
7. G von Minckwitz A du Bois M Schmidt N Maass T Cufer FE de Jongh E Maartense C Zielinski M Kaufmann W Bauer, et al. 2009 Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study J Clin Oncol 27 1999 2006 10.1200/JCO.2008.19.6618
8. D Cameron M Casey M Press D Lindquist T Pienkowski CG Romieu S Chan A Jagiello-Gruszfeld B Kaufman J Crown, et al. 2008 A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses Breast Cancer Res Treat 112 533 543 1:CAS:528: DC%2BD1cXhtl2mu7bI 10.1007/s10549-007-9885-0 18188694
9. CH Barrios MC Liu SC Lee L Vanlemmens JM Ferrero T Tabei X Pivot H Iwata K Aogi R Lugo-Quintana, et al. 2010 Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer Breast Cancer Res Treat 121 121 131 1:CAS:528:DC%2BC3cXkvVymt70%3D 10.1007/s10549-010-0788-0 20339913
10. GW Sledge Jr Y Gökmen-Polar 2006 Protein kinase C-beta as a therapeutic target in breast cancer Semin Oncol 33 S15 S18 1:CAS:528: DC%2BD28XnsFWhtbo%3D 10.1053/j.seminoncol.2006.03.019 16797377
11. JR Graff AM McNulty KR Hanna BW Konicek RL Lynch SN Bailey C Banks A Capen R Goode JE Lewis, et al. 2005 The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts Cancer Res 65 7462 7469 1:CAS:528:DC%2BD2MXns1Wqsrc%3D 10.1158/0008-5472.CAN-05-0071 16103100
12. Eli Lilly and Company (2005) Investigator's brochure. LY317615 (enzastaurin)
13. MJ Robertson BS Kahl JM Vose S de Vos M Laughlin PJ Flynn K Rowland JC Cruz SL Goldberg L Musib, et al. 2007 Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma J Clin Oncol 25 1741 1746 1:CAS:528:DC%2BD2sXlvFyktbg%3D 10.1200/JCO.2006.09.3146 17389337
14. DR Camidge S Gail Eckhardt L Gore CL O'Bryant S Leong M Basche SN Holden L Musib J Baldwin C Darstein, et al. 2008 A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors Anticancer Drugs 19 77 84 1:CAS:528:DC%2BD2sXhtlCrur3L 10.1097/CAD.0b013e3282f077b3 18043132
15. National Cancer Institute (NCI) (2003) Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/protocoldevelopment/ electronic-applications/docs/ctcaev3.pdf. Accessed July 10, 2006
16. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij GM Van AT van Oosterom MC Christian, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, and National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10.1093/jnci/92.3.205 10655437
17. J Ansari DH Palmer DW Rea SA Hussain 2009 Role of tyrosine kinase inhibitors in lung cancer Anticancer Agents Med Chem 9 569 575 1:CAS:528:DC%2BD1MXos1als7s%3D 19519298
18. TS Mok YL Wu S Thongprasert CH Yang DT Chu N Saijo P Sunpaweravong B Han B Margono Y Ichinose, et al. 2009 Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 947 957 1:CAS:528:DC%2BD1MXhtVygsbfK 10.1056/NEJMoa0810699 19692680
19. Roche Laboratories, Inc. (1999) Xeloda (capecitabine) label information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2005/020896s016lbl.pdf. Accessed May 17, 2010
20. B Reigner J Verweij L Dirix J Cassidy C Twelves D Allman E Weidekamm B Roos L Banken M Utoh, et al. 1998 Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients Clin Cancer Res 4 941 948 1:CAS:528:DyaK1cXisFeltLs%3D 9563888
21. E Vrdoljak BP Mise B Lukic Z Curic L Boskovic I Tica 2010 Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine-case report Onkologie 33 53 56 10.1159/000264615 20164663
22. L Li J Li K Yang J Tian T Sun W Jia P Zhang K Yi 2010 Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer Future Oncol 6 201 207 1:CAS:528:DC%2BC3cXhvVGqtLs%3D 10.2217/fon.09.162 20146579
23. P Pronzato 2008 New therapeutic options for chemotherapy-resistant metastatic breast cancer: the epothilones Drugs 68 139 146 1:CAS:528: DC%2BD1cXmsV2msrw%3D 10.2165/00003495-200868020-00001 18197722
24. DK Frye 2010 Advances in breast cancer treatment: the emerging role of ixabepilone Expert Rev Anticancer Ther 10 23 32 1:CAS:528:DC%2BD1MXhsFKns7%2FN 10.1586/era.09.158 20014882